

#### Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

#### **Table of Contents**

:

Data Supplement 1: Table 1: Patient and Disease Characteristics Table 2: Outcomes and Adverse Events

Data Supplement 2: Systematic Review and Meta-analysis

Data Supplement 3: Literature Search Strategy

Data Supplement 4: QUOROM Diagram

Data Supplement 5: World Health Organization - Definition of Palliative Care

Data Supplement 6: Pancreatic Protocol Computerized Tomography (CT)

# **Table 1: Patient and Disease Characteristics**

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex	-	Perform-	<b>T</b>		Previous
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
Oettle et al., 2014	OFF	76	62	40	36	Karnofsky 70-80: 35 90-100: 41	NR	NR	NR
CONKO-003									
Von Hoff et al., 2013	nab-Paclitaxel plus Gemcitabine	431	62	245	186	Karnofsky 100: 69 (16%) 90: 179 (42%) 80: 149 (35%) 70: 30 (7%) 60: 2 (<1%)	Head: 191 (44%) Body: 132 (31%) Tail: 105 (24%) Unknown: 3 (1%)	Level of CA 19-9 Normal: 60 (16%) ULN to <59x ULN: 122 (32%) >/= 59x ULN: 197 (52%) CA 19-9 U/ml: 2293.7 range 1.9- 6159	Chemo: 23 (5%) Radiation: 19 ( 4%) Whipple: 32 (7%) Stent: 80 (19%)

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year Reference	[or] Comparisons	# of Pts	Median Age	Sex Male	Female	Perform- ance	Location	Markers	Previous Treatment
	Gemcitabine alone	430	63	257	173	Status Karnofsky 100: 69 (16%) 90: 199 (46%) 80: 128 (30%) 70: 33 (8%) 60: 0 (0%)	Head: 180 (42%) Body: 136 (32%) Tail: 110 (26%) Unknown: 4 (1%)	Level of CA 19-9 Normal: 56 (15%); ULN to <59x ULN 120 (32%); >/= 59x ULN 195 (53%) CA 19-9 U/ml: 2759 range 0.3- 12,207	Chemo: 12 (3%) Radiation: 11 (3%) Whipple: 30 (7%) Stent: 68 (16%)
Rougier et al.,	Gemcitabine plus placebo	275	61	157	118	WHO 0: 102 1: 154 2: 19	Head: 117 Body: 41 Tail: 45 Entire pancreas: 72 Other: 0	NR	NR
2013	Gemcitabine plus aflibercept	271	62	160	111	WHO 0: 102 1: 152 2: 17	Head: 132 Body: 41 Tail: 46 Entire Pancreas: 50 Other: 2		

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex		Perform-			Previous
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
Goncalves et al., 2012 BAYPAN G	Gemcitabine plus placebo	52	64	32	20	WHO 0: 18 1: 30 2: 3 NA: 1	ND	CA 19-9 Median 424 (1.3-3300)	NR
	Gemcitabine plus sorafenib	52	61	30	22	WHO 0: 16 1: 26 2: 5 NA: 5	NR	CA 19-9 Median 471 (1.2-21500)	INK
Conroy et al.,	FOLFIRINOX	171	61	106	65		Head: 67 Body: 53 Tail: 45 Multicentric: 6	ND	Stent: 27
2011	Gemcitabine	171	61	105	66	NR	Head: 64 Body: 58 Tail: 45 Multicentric: 5/171	NR	Stent: 22
Kindler et al., 2011	axitinib plus gemcitabine	314	61	191	123	WHO 0: 147 1: 162 Missing: 11	NR	NR	NR
	placebo plus gemcitabine	316	62	188	128	WHO 0: 158 1: 154 Missing: 4	58 54		

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex		Perform- ance	Location	Markers	Previous
Reference	Comparisons		Age	Male	Female	Status	Location	Warkers	Treatment
da Cunha Santos et al.,	Gemcitabine vs gemcitabine plus erlotinib in KRAS mutant patients	92	62.2	47	45	WHO 0:16 1:57 2:19 Unknown: 0			
	Gemcitabine vs gemcitabine plus erlotinib in KRAS wild type patients	25	65.6	17	8	WHO 0: 7 1: 14 2: 3 Unknown:1	NR	NR	
2010 NCIC CTG PA.3	Gemcitabine vs gemcitabine plus erlotinib in EGFR FISH+ patients	50	61.0	32	18	WHO 0:11 1:24 2:14 Unknown:1			NR
	Gemcitabine vs gemcitabine plus erlotinib in EGFR FISH- patients	57	64.7	30	27	WHO 0:12 1:35 2:10 Unknown:0			
Moinpour et al., 2010	Gemcitabine	359	65	197	162	WHO 0-1:312 2:47	NR	NR	Chemo: 14 Pancreatectomy: 36

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	Previous			
Year	[or]	# of Pts	Median	Sex		Perform-			Previous			
Reference	Comparisons	AgeMaleFemaleance StatusLocation		Markers								
	Gemcitabine plus cetuximab	361	64	188	173	WHO 0-1: 314 2: 47			Pancreatectomy:			
Colucci et at., 2010	Gemcitabine	199	63	113	86	Karnofsky =70:33 /=80: 166	Head: 91 Body: 52 Tail: 26 Head + Body:10 Body + Tail:18 Head + Body + Tail:1 Unknown:1	ND	Surgery: 47			
GIP-1	Gemcitabine plus Cisplatin	201	63	125	73	Karnofsky =70:36 /=80: 165	Head: 101 Body: 34 Tail: 20 Head + Body: 6 Body + Tail: 39 Head + Body + Tail:1 Unknown:0	NR	Surgery: 56			
Dahan et al., 2010 FFCD 0301	LV5FU2-CDDP	102	62	65	37	WHO 0: 28 1: 51 2: 22 Not Determined : 1	Head: 57 Other: 44 Unknown: 1	CEA Median: 9 (0-2224) CA 19-9 Median: 565 (0-862200)	Chemo: 0 Radiation: 1 Resection: 13 Drainage: 4 Other Surgery: 6 Deudenal Stent: 10 Radiological/end oscopic drainage: 22			
	Gemcitabine	100	65	65	35	WHO 0: 30 1: 53	Head: 49 Other: 50 Unknown: 1	CEA Median: 7 (1-3604)	Chemo: 3 Radiation: 2 Resection: 14			

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex		Perform-			Previous
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
						2: 14 Not Determined : 3		CA 19-9 Median: 560 (1-156649)	Drainage: 8 Other Surgery: 6 Deudenal Stent: 5 Radiological/end oscopic drainage: 11
Cunningham	Gemcitabine	266	62	153	113	WHO 0: 56 1: 161 2: 49	Head: 185 Body: 36 Tail: 30 Head + Body: 7 Body + Tail: 7 Unknown: 5		
Cunningham et al., 2009	Gemcitabine plus Capecitabine	267	62	160	107	WHO 0: 66 1: 149 2: 52	Head: 190 Body: 29 Tail: 25 Head + Body: 10 Body + Tail: 10 Unknown: 4	NR	NR
Van Cutsem	Gemcitabine- erlotinib plus placebo	301	61	188	113	NR	Head: 165 Body: 65 Tail: 67	NR	Radiation: 5 Antimetobolites: 14
et al., 2009	Gemcitabine- erlotinib plus Bevacizumab	306	62	174	132		Head: 157 Body: 79 Tail: 68		Radiation: 12 Antimetobolites: 12
Poplin et al., 2009 E6201	Gemcitabine	275	64	155	120	NR	NR	CA 19-9 Median 1961 (167- 12024) CEA Median: 5.7 (2.3-30.9)	Chemo: 15 Radiation: 21 Surgery: 43

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex		Perform-			Previous
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
	Gemcitabine fixed-dose rate infusion	277	61	160	117			CA 19-9 Median: 1148 (136- 9651) CEA Median: 5.9 (2.4-30.1)	Chemo: 17 Radiation: 23 Surgery: 42
	Gemcitabine plus oxaliplatin	272	63	124	148			CA 19-9 Median: 1077 (90- 9301) CEA Median: 6.3 (2.4 -35.5)	Chemo: 10 Radiation: 21 Surgery: 32
Bernhard et al., 2008	Capecitabine plus Gemcitabine	160	62	86	74	Karnofsky 90-100: 84 60-80: 76	NR	NR	NR
SAKK 44/00- CECO/PAN.1 .3.001	Gemcitabine	159	62	85	74	Karnofsky 90-100: 84 60-80: 75			
Herrmann et	Capecitabine plus Gemcitabine	160	NR	86	74	Karnofsky 90-100: 84 60-80: 76	NR	NR	NR
al., 2007	Gemcitabine	159		85	74	Karnofsky 90-100: 84 60-80: 75		IVIK	NK
Moore et al., 2007	Erlotinib plus Gemcitabine	285	63.7	136	149	WHO 0: 85 1: 145 2: 54	NR	NR	FU or Gem given concurrently as a radiosensatizer only: 20 Radiation: 22 Resection: 19

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	
Year	[or]	# of Pts	Median	Sex		Perform-			Previous
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
	Placebo plus Gemcitabine	284	64.0	162	122	WHO 0: 85 1: 174 2: 52			FU or Gem given concurrently as a radiosensatizer only: 25 Radiation: 25 Resection: 29
Abou-Alfa et	Exatecan plus Gemcitabine	174	63.0	92	83	Karnofsky 90-100: 90 70-80: 81 60: 4	ND	CA 19-9 Median: 1053 (0.8- 1237761)	NR
al., 2006	Gemcitabine	174	62.3	99	99	Karnofsky 90-100: 90 70-80: 82 60: 2	NR	CA 19-9 Median: 597 (1.3- 304332)	
Stathopoulos	irinotecan plus gemcitabine	60	64	39	21	WHO 0-1: 52 2: 8	ND	NR	Surgery: 11 No Prior Treatment: 49
et al., 2006	gemcitabine	70	64	42	28	WHO 0-1: 8 2: 10	NR		Surgery: 16 No Prior Treatment: 54
Heinemann et	gemcitabine plus cisplatin	98	64	64	34	Karnofsky 100: 20 90: 24 80: 27 70: 8	Head: 55 Body: 19 Tail: 24	ND	ND
al., 2006	gemcitabine	97	66	60	37	Karnofsky 100: 19 90: 21 80: 29 70: 13	Head: 55 Body: 24 Tail: 18	NR	NR
Reni et al., 2005	PEFG	52	62	24	28	Karnofsky >70: 37 = 70: 15</td <td>NR</td> <td>NR</td> <td>NR</td>	NR	NR	NR

Author	Interventions		Patient C	haracte	ristics		Disease Characte	eristics	Freatment NR Radiation: 11 Radiation: 14		
Year	[or]	# of Pts	Median	Sex		Perform-			Provious		
Reference	Comparisons		Age	Male	Female	ance Status	Location	Markers	Previous Treatment		
	Gemcitabine	47	59	24	23	Karnofsky >70: 35 = 70: 12</td <td></td> <td></td> <td></td>					
Louvet et al., 2005	Gemcitabine	156	60.1	53	47	WHO 0: 28 1: 54 2: 18	Head: 50 Body: 37 Tail: 13	Median: 1424	ND		
	Gemcitibine plus oxaliplatin	157	61.3	60	40	WHO 0: 31 1: 52 2: 17	Head: 54 Body: 27 Tail: 19	Median: 965	- INK		
Rocha Lima et	Gemcitabine plus Irinotecan	180	63.2	103	73	WHO 0:51 1:90 2:34 3:1 missing:4		ND	Radiation: 11		
al., 2004	Gemcitabine	180	60.2	96	73	WHO 0:42 1:91 2:36 3:0 missing:11	- NR	NR	Radiation: 14		
Berlin et al., 2002	Gemcitabine	162	64.3	87	75	WHO 0:56 1:84 2:22	Head:81 Body: 19 Tail: 27 Unknown: 35	ND	ND		
E2297	Gemcitabine plus 5-FU	160	65.8	83	77	WHO 0:36 1:102 2:22	Head: 87 Body: 36 Tail: 21 Unknown: 17	NR	NR		
Maisey et al., 2002	PVI 5-FU	107	62	68	39	WHO 0:18 1:59	NR	NR	NR		

Author	Interventions		Patient C	haracte:	ristics		Disease Charact	eristics	
Year Reference	[or]	# of Pts   Median   Sex   Perform-			Previous				
	Comparisons		Age	Male	Female	ance Status	Location	Markers	Treatment
						2:28			
						3: 1			
						WHO			
	PVI 5-FU plus					0:20			
	mitomycin	102	61	62	40	1:54			
						2:24			
						3:1			

Abbreviations: CONKO, Charité Onkologie; OFF, Oxaliplatin, fluoruracil, plus folinic acid; FF, fluoruracil, plus folinic acid; NR, not reported; CA, cancer antigen; ULN, upper limit of normal; Chemo, chemotherapy; WHO, World Health Organization; FOLFIRINOX, folinic acid, fluorouracil, irinotecan, oxaliplatin; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; EGFR, Epidermal growth factor receptor; FISH, fluorescence in situ hybridization; GIP, Gruppo Italiano Pancreas; FFCD, Fédération Francophone de Cancérologie Digestive; LV5FU2-CDDP, 5-fluorouracil, folinic acid and cisplatin combination ; CEA, Carcinoembryonic antigen; SAKK, Swiss Group for Clinical Cancer Research; CECOG, Central European Cooperative Oncology Group; FU, fluorouracil; Gem, Gemcitabine; PEFG, cisplatin, epirubicin, 5-fluorouracil, gemcitabine; PVI, protracted venous infusion

# Table 2: OUTCOMES: Survival (OS), progression free survival (PFS) and disease free survival (DFS) and adverse events (AEs)

Study	Intervention	# of patients	Outcome
	OFF	76	The median overall survival 5.9 months; 95% CI, 4.1 to 7.4) (hazard ratio [HR], 0.66; 95% CI, 0.48 to 0.91; log-rank P .010). Time to progression (2.9 months; 95% CI, 2.4 to 3.2) was significantly extended also (HR, 0.68; 95% CI, 0.50 to 0.94; log-rank
Oettle et al., 2014 CONKO-003	FF	84	<ul> <li>P019).</li> <li>Rates of adverse events were similar between treatment arms, with the exception of grades 1 to 2 neurotoxicity, which were reported in 29 patients (38.2%) in the [(P001).</li> <li>The median overall survival (3.3 months; 95% CI, 2.7 to 4.0) was significantly improved (hazard ratio [HR], 0.66; 95% CI, 0.48 to 0.91; log-rank P010).</li> <li>Time to progression (2.0 months; 95% CI, 1.6 to 2.3) was significantly extended also (HR, 0.68; 95% CI, 0.50 to 0.94; log-rank P019).</li> <li>Rates of adverse events were similar between treatment arms, with the exception of grades 1 to 2 neurotoxicity, which were reported in and six patients (7.1%) in</li> </ul>
Von Hoff et al., 2013	nab-Paclitaxel plus Gemcitabine	431	the OFF and FF groups, (P.001).The median overall survival was 8.5 months (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001).

Study	Intervention	# of patients	Outcome
			CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001).
			The most common adverse events of grade 3 or higher were neutropenia (38%), fatigue (17%); and neuropathy (17% Febrile neutropenia occurred in 3% neuropathy of grade 3 or >r higher improved to grade 1 or lower in a median of 29 days
	Gemcitabine alone	430	The median overall survival was 6.7 months (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001).
			The survival rate was 22% at 1 year and 4% at 2 years.
			The median progression-free survival was 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001);
			The response rate according to independent review was 23% versus 7% in the two groups (P<0.001).
			The most common adverse events of grade 3 or higher were 27%; fatigue .7%, and neuropathy 1%). Febrile neutropenia occurred in 1% of the patients; neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 day
Rougier et al., 2013	Gemcitabine plus placebo	275	The study was stopped for futility following a planned interim analysis of OS in 427 randomized patients. With a median follow-up of 7.9 months, based on the 546 patients at study termination.

Study	Intervention	# of patients	Outcome
	Gemcitabine plus aflibercept	271	Median OS was 7.8 months in the gemcitabine plus placebo arm (n=275) versus 6.5 months in the gemcitabine plus aflibercept arm (n=271), which was not significant (hazard ratio 1.165, 95% confidence interval (CI) 0.921-1.473, $p=0.2034$ ).
			Median progression-free survival was 3.7 months in both arms. Treatment discontinuations due to adverse events were more frequent in the aflibercept than in the placebo-containing arm (23% versus 12%).
	Gemcitabine plus placebo	52	Median and the 6-month PFS were 5.7 months and 48%. ( $P = 0.902$ , stratified log-rank test)
			Median overall survivals was 9.2 ( $P = 0.231$ , log-rank test).
Goncalves et al., 2012			Overall response rates were similar (19%).
BAYPAN	Gemcitabine plus sorafenib	52	The median and the 6 month PFS were 3.8 months and 33% ( $P = 0.902$ , stratified log-rank test), respectively
			The median overall survivals was 8 months ( $P = 0.231$ , log-rank test).
			The overall response rates were similar 23%.
	FOLFIRINOX	171	The median overall survival was 11.1 months, (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001).
Conroy et al., 2011			Median progression-free survival was 6.4 months , (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001)
			The objective response rate was 31.6%, (P<0.001).

Study	Intervention	# of patients	Outcome
			More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabinee group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001
	Comoitabino	171	The median overall survival was 6.8 months, (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001).
	Gemcitabine	171	Median progression-free survival was 3.3 months , (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001).
			The objective response rate was 9.4, (P<0.001)
	Axitinib plus gemcitabine	314	At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed.
			Median overall survival was 8.5 months (95% CI 6.9-9.5) for gemcitabine plus axitinib (n=314, data missing for two patients; hazard ratio 1.014, 95% CI 0.786-1.309; one-sided p=0.5436).
Kindler et al., 2011			The most common grade 3 or higher adverse events for gemcitabine plus axitinib were hypertension (20 [7%] events, abdominal pain (20 [7%], fatigue (27 [9%], and anorexia (19 [6%]/
	Placebo plus	316	Median overall survival was 8.3 months (6.9-10.3) (n=316; hazard ratio 1.014, 95% CI 0.786-1.309; one-sided p=0.5436).
	Gemcitabine		The most common grade 3 or higher adverse events for gemcitabine plus placebo were hypertension 5 [2%] events, abdominal pain (17 [6%]), fatigue and 21

Study	Intervention	# of patients	Outcome
			[7%]), and anorexia and 11 [4%]).
	Gemcitabine vs gemcitabine plus erlotinib in KRAS mutant patients	92	KRAS analysis was successful in 117 patients, and EGFR FISH analysis was
da Cunha Santos et al.,	Gemcitabine vs gemcitabine plus erlotinib in KRAS wild type patients	25	successful in 107 patients. KRAS mutations were identified in 92 patients (78.6%), and EGFR amplification or high polysomy (FISH-positive results) we identified in 50 patients (46.7%). The hazard ratio of death between gemcitabine /erlotinib and gemcitabine /placebo was 0.66 (95% confidence interval [CI], 0.28-1.57) for patients with wild-type KRAS and 1.07 (95% CI,
2010 NCIC CTG PA.3	Gemcitabine vs gemcitabine plus erlotinib in EGFR FISH+ patients	50	0.68-1.66) for patients with mutant KRAS (P value for interaction = .38), and the hazard ratio was 0.6 (95% CI, 0.34-1.07) for FISH-negative patients and 0.90 (95% CI, 0.49-1.65) for FISH-positive patients (P value for interaction = .32).
	Gemcitabine vs gemcitabine plus erlotinib in EGFR FISH- patients	57	

Study	Intervention	# of patients	Outcome
Moinpour et al., 2010	Gemcitabine Gemcitabine plus cetuximab	359 361	The two treatment arms did not differ statistically in the percentage of patients with successful worst pain palliation. Longitudinal analyses showed significantly improved emotional well-being for patients on both arms by weeks 13 and 17 (P < .01 and P < .001). An exploratory longitudinal analysis of worst pain showed significant decreases at all time points for both arms (P < .01 and P < .001). Significant treatment arm differences for either worst pain or emotional well-being were not observed at any of the assessment times.
Colucci et at., 2010 GIP-1	Gemcitabine Gemcitabine plus Cisplatin	199 201	Median overall survival was 8.3 months (HR, 1.10; 95% CI, 0.89 to 1.35; P = .38). Median progression-free survival was 3.9 months (HR, 0.97; 95% CI, 0.80 to 1.19; P = .80). The objective response rate was 10.1% in A (P = .37). Clinical benefit was experienced by 23.0% in (P = .057). Median overall survival was 7.2 months (HR, 1.10; 95% CI, 0.89 to 1.35; P = .38). Median progression-free survival was 3.8 months, (HR, 0.97; 95% CI, 0.80 to 1.19; P = .80). Clinical benefit was experienced by 15.1% in B (P = .057). The objective response rate was 12.9% (P = .37).
			Combination therapy produced more hematologic toxicity, without relevant differences in non-hematologic toxicity.

Study	Intervention	# of patients	Outcome
Dahan et al., 2010 FFCD 0301	LV5FU2- CDDP Gemcitabine	102	<ul> <li>Median OS in Arm A was 6.6 months. (p = 0.85).</li> <li>Median progression-free survival was similar between Arms A and B.</li> <li>More grade 3/4 toxicities were observed when LV5FU2-CDDP was administered as a first-line treatment at 79% (p = 0.018)</li> <li>Median OS in 8.0 months (p = 0.85).</li> <li>Median progression-free survival was similar between Arms A and B.</li> <li>More grade 3/4 toxicities were observed when gemcitabine was administered as a first-line treatment 64% (p = 0.018).</li> </ul>
Cunningham et al., 2009	Gemcitabine Gemcitabine plus Capecitabine	266 267	Objective response rate with GEM was 12.4%; P = .034) Objective response rate with GEM-CAP was 19.1%; P = .034) Progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone. This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).

Study	Intervention	# of patients	Outcome
	Gemcitabine- erlotinib plus placebo	301	Median OS was 7.1 (hazard ratio [HR], 0.89; 95% CI, 0.74 to 1.07; P = .2087); this difference was not statistically significant.
Van Cutsem et al., 2009	Gemcitabine- erlotinib plus Bevacizumab	306	Median OS was 6.0 months (hazard ratio [HR], 0.89; 95% CI, 0.74 to 1.07; P = .2087); this difference was not statistically significant. Adding bevacizumab to gemcitabine-erlotinib significantly improved PFS (HR, 0.73; 95% CI, 0.61 to 0.86; P = .0002). Treatment with bevacizumab plus gemcitabine-erlotinib was well tolerated: safety data did not differ from previously described safety profiles for individual drugs
Poplin et al., 2009 E6201	Gemcitabine Gemcitabine fixed-dose rate infusion Gemcitabine	275 277 272	<ul> <li>Median survival and 1-year survival were 4.9 months (95% CI, 4.5 to 5.6) and 16%, (95% CI, 5.4 to 6.9), (HR, 0.83; stratified log-rank P = .04.</li> <li>The median survival and 1-year survival were 6.2 months (HR, 0.83; stratified log-rank P = .04), 21% and (95% CI, 4.9 to 6.5). Grade 3/4 neutropenia and thrombocytopenia were greatest with GEM FDR.</li> <li>The median survival and 1-year survival were 5.7 months (95% CI, 4.9 to 6.5) and 21% (HR, 0.88; stratified log-rank P = .22).</li> </ul>
	plus oxaliplatin		*None of these differences met the prespecified criteria for significance. Survival was 4 months for those with metastatic disease.

Study	Intervention	# of patients	Outcome
	Capecitabine plus Gemcitabine	160	Clinical benefit response of 19% treated with GemCap with a median duration of 9.5 weeks, respectively ( $P < .02$ ). 54% of patients treated with GemCap had no Clinical benefit response.
Bernhard et al., 2008 SAKK	Gemcitabine	159	Clinical benefit response of 19% treated with Gem with a median duration of 9.5 weeks, $(P < .02)$
44/00- CECO/PAN.			60% treated with Gem had no clinical benefit response (remaining patients were not assessable).
1.3.001			There was no treatment difference in QOL (n = 311). QOL indicators were improving under chemotherapy (P < .05). These changes differed by the time to failure, with a worsening 1 to 2 months before treatment failure (all P < .05).
	Capecitabine plus Gemcitabine	160	Median OS was 8.4 months, (P = .234). Post hoc analysis in patients with good KPS (score of 90 to 100) showed a significant prolongation of median OS of 10.1, P = .014).
Herrmann et al., 2007	Gemcitabine	159	Median OS time was 7.2 months ( $P = .234$ ). Post hoc analysis in patients with good KPS (score of 90 to 100) showed a significant reduction of median OS time of 7.4 months, $P = .014$ ). The overall frequency of grade 3 or 4 adverse events was similar in each arm. Neutropenia was the most frequent grade 3 or 4 adverse event in both arms

Study	Intervention	# of patients	Outcome
Moore et al., 2007	Erlotinib plus Gemcitabine Placebo plus Gemcitabine	285	Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/ gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; $P = .038$ , adjusted for stratification factors; median 6.24 months). One-year survival was 23% $P = .023$ ). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; $P = .004$ ). Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/ gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; $P = .038$ , adjusted for stratification factors; 5.91 months). One-year survival was 17%; $P = .023$ ). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine.
Abou-Alfa et al., 2006	Exatecan plus Gemcitabine	174	Median survival time was 6.7 months.and 6.2 months for gemcitabine alone (P = .52). One complete response (CR; < 1%) and 11 partial responses (PRs; 6.3%) were observed. Grade 3 and 4 toxicities neutropenia (30%); thrombocytopenia (15%).

Study	Intervention	# of patients	Outcome
	Gemcitabine	174	Median survival time was 6.2 months (P = .52). One CR (< 1%) and eight PRs (4.6%) were observed. Grade 3 and 4 toxicities neutropenia (15%); thrombocytopenia (4%).
Stathopoulos et al., 2006	Irinotecan plus Gemcitabine Gemcitabine	60 70	<ul> <li>The overall response rate was 15% (95% CI 5.96-24.04 and 95% CI 2.97-17.03, respectively; P=0.387).</li> <li>The median time to tumor progression was 2.8 months and median survival time was 6.</li> <li>One-year survival was 24.3%.</li> <li>The overall response rate was 10% (95% CI 5.96-24.04 and 95% CI 2.97-17.03, respectively; P=0.387).</li> <li>The median time to tumor progression was 2.9 months and median survival time was 6.5 months.</li> <li>One-year survival was 21.8%.</li> </ul>
Heinemann et al., 2006	Gemcitabine plus Cisplatin	98	<ul> <li>Median progression-free survival of 5.3 months; hazard ratio [HR] = 0.75; P = .053).</li> <li>Median overall survival was superior at 7.5 months), an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15).</li> <li>Tumor response rate was 10.2%.</li> <li>Tumor response rates were comparable between treatment arms (10.2% v 8.2%).</li> </ul>

Study	Intervention	# of patients	Outcome
	Gemcitabine	97	The rate of stable disease was, however, greater in the combination arm at 60.2% $P < .001$ ). Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms. Median progression-free survival of 3.1 months; hazard ratio [HR] = 0.75; P = .053). Median overall survival was 6.0 months, an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15). Tumor response rate was 8.2%. The rate of stable disease was, however, greater in the combination arm was 40.2%; P < .001). Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.
	PEFG	52	The largest differences between arms favored PEFG. Expressed as improvement greater than or equal to 10 points from baseline (PEFG/gemcitabine), these were: emotional function $(42/18\%)$ for fatigue $(41/17\%)$ OOL $(55/20\%)$ pair $(64/41\%)$ and flatulance
Reni et al., 2005	Gemcitabine	47	function (43/18%), fatigue (41/17%), QOL (55/29%), pain (64/41%), and flatulence (50/26%). Only change in sexual function favored gemcitabine (19/42%). Physical function, fatigue, appetite, and satisfaction with healthcare improved in 40-46% of partial responders compared with 0-12% of patients with stable disease.
Louvet et al., 2005	Gemcitabine plus oxaliplatin	157	Response rate (26.8%; $P = .04$ ) Progression-free survival (5.8; $P = .04$ ), ] Clinical benefit (38.2%; $P = .03$ ).

Study	Intervention	# of patients	Outcome
			Median overall survival (OS) was 9.0 (P = .13). Higher incidence of National Cancer Institute Common Toxicity Criteria grade 3 and 4 toxicity per patient was observed for platelets (14.0%), vomiting (8.9%), and neurosensory symptoms (19.1%).
	Gemcitabine	157	Response rate (17.3%, P = .04) Progression-free survival (3.7 months; P = .04). Clinical benefit ( 26.9%, P = .03). Median overall survival (OS) for 7.1 months, respectively (P = .13). Grade 3 and 4 toxicity per patient was observed for platelets 3.2%, vomiting (3.2%), and neurosensory symptoms (0%).
Rocha Lima et al., 2004	Gemcitabine plus Irinotecan	180	<ul> <li>Median survival times were 6.3 months for IRINOGEM (95% CI, 4.7 to 7.5 months) and 6.6 months for GEM (95% CI, 5.2 to 7.8 months; log-rank P =.789).</li> <li>Tumor response rates were 16.1% (95% CI, 11.1% to 22.3%) for IRINOGEM (chi2 P &lt;.001).</li> <li>Median TTP was 3.5 months for IRINOGEM (log-rank P =.352).</li> <li>However, subset analyses in patients with locally advanced disease suggested a TTP disadvantage with IRINOGEM (median, 7.7 v 3.9 months). CA 19-9</li> </ul>

Study	Intervention	# of patients	Outcome
	Gemcitabine	180	<ul> <li>progression was positively correlated with tumor progression.</li> <li>The incidence of grade 3 diarrhea was higher in the IRINOGEM group but grade 3 to 4 hematologic toxicities and quality-of-life outcomes were similar.</li> <li>Median survival times were 6.6 months (95% CI, 5.2 to 7.8 months; log-rank P =.789).</li> <li>Tumor response rates were and 4.4% (95% CI, 1.9% to 8.6%) (chi2 P &lt;.001).</li> <li>Median TTP was 3.0 months (log-rank P =.352).</li> <li>Subset analyses in patients with locally advanced disease suggested a TTP disadvantage with GEM (median, 3.9 months). CA 19-9 progression was positively correlated with tumor progression.</li> <li>The incidence of grade 3 diarrheas was lower but grade 3 to 4 hematologic toxicities and quality-of-life outcomes were similar.</li> </ul>
Berlin et al., 2002 E2297	Gemcitabine	162	<ul> <li>Median survival was 5.4 months (P =.09).</li> <li>Progression-free survival was 2.2 months, (P =.022).</li> <li>Objective responses were uncommon and were observed in only 5.6% of patients treated with gemcitabine.</li> <li>Most toxicities were hematologic or gastrointestinal; no significant differences were noted between the two treatment arms.</li> </ul>

Study	Intervention	# of patients	Outcome
	Gemcitabine plus 5-FU	160	<ul> <li>Median survival was 6.7 months (P =.09).</li> <li>Progression-free survival was 3.4 months (P =.022).</li> <li>Objective responses were uncommon and were observed in only 6.9%</li> <li>Most toxicities were hematologic or gastrointestinal; no significant differences</li> </ul>
Maisey et al., 2002	PVI 5-FU PVI 5-FU plus mitomycin	107	<ul> <li>were noted between the two treatment arms.</li> <li>The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% 95% (P =.04).</li> <li>Median failure-free survival was 2.8 months (P =.14).</li> <li>Median survival was 5.1 months (P =.34).</li> <li>Toxicities were mild. No differences in infection were seen. No patients developed hemolytic uremic syndrome.</li> <li>The overall response rate was 17.6%; (95% confidence interval [CI] 10.3% to 25.1%, (P =.04).</li> <li>Median failure-free survival was 2 3.8 months (P =.14).</li> <li>Median survival was 6.5 months (P =.34).</li> <li>Toxicities in both arms were mild. There was an increased incidence of</li> </ul>
			<ul><li>neutropenia in the 5-FU plus MMC arm (P &lt;.01), although no differences in infection were seen.</li><li>No patients developed hemolytic uremic syndrome.</li><li>Global QOL improved significantly after 24 weeks of treatment compared with</li></ul>

Study	Intervention	# of patients	Outcome
			baseline for patients receiving 5-FU plus MMC, although there was no statistically significant difference in QOL between arms.

Abbreviations: CONKO, Charité Onkologie; OFF, Oxaliplatin, fluoruracil, plus folinic acid; FF, fluoruracil, plus folinic acid; OS, overall survival; PFS, progression free survival; APC, advanced pancreatic cancer; FOLFIRINOX, folinic acid, fluorouracil, irinotecan, oxaliplatin; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; EGFR, Epidermal growth factor receptor; FISH, fluorescence in situ hybridization; HRQL, health-related quality of life; GIP, Gruppo Italiano Pancreas; FFCD, Fédération Francophone de Cancérologie Digestive; LV5FU2-CDDP, 5-fluorouracil, folinic acid and cisplatin combination; GEM, Gemcitabine; CAP, Capecitabine; FDR, fixed dose rate; GEMOX, gemcitabine and oxaliplatin; SAKK, Swiss Group for Clinical Cancer Research; CECOG, Central European Cooperative Oncology Group; CBR, clinical benefit response; QOL, quality of life; PEFG, cisplatin, epirubicin, 5-fluorouracil, gemcitabine; IRINOGEM, irinotecan plus gemcitabine; FU, fluorouracil; PVI, protracted venous infusion; MMC, mitomycin

Author/Title	Journal	Patient and Study	Results	Conclusion
		Characteristics		
Sgouros J (1),	Acta	A Medline and	Fourteen papers and five	Overall treatment-related deaths represent
Maraveyas A	Oncol.	EMBASE search was	abstracts met our criteria and	a very small percentage of the deaths
	2008;47(	done for chemotherapy	are included in our review.	happening during the 3-month period, and
Excess	3):337-	or chemotherapy based	Six thousand two hundred and	are unlikely to be under-reported given
premature (3-	46.	phase III studies in	twelve patients participated in	the Good Clinical Practice oversight of
month)		advanced pancreatic	these trials and 1,447 (23.3%)	these trials. Progressive cancer is likely to
mortality in		cancer published since	died in the first 3-month	be an important cause of early mortality
advanced		1997. Similar search	period. Figures were worse in	but given the very select nature of the
pancreatic		was done at the	patients with metastases and	trial-related population this cannot explain
cancer could be		American Society of	poorer performance status.	the phenomenon of 3-month early death
related to fatal		Clinical Oncology web	Assuming that most deaths	burden of 23.3%. Our hypothesis,
vascular		site for abstracts	during treatment happened	supported by multiple autopsy series, is
thromboemboli		presented since 2000.	during the first 3-months,	that early death burden in advanced
c events. A		Three months mortality	cause of death was reported in	pancreatic cancer trial patients is likely to
hypothesis		was based on the	only 40 cases (2.8%).	be due to under-reported vascular
based on a		survival curves	Progressive cancer was	thromboembolic events.
systematic		presented.	reported as cause of death in	Thromboprophylaxis needs to be
review of phase			21 of these cases. Less	addressed in future trials.
			frequent causes of death were	
chemotherapy studies in			reported to be infections, 'complications of cancer',	
advanced			thromboembolic events and	
pancreatic			renal failure.	
cancer.				
Yang ZY (1),	PLoS	PubMed, EMBASE,	Sixteen studies containing	Gemcitabine plus erlotinib represent a
Yuan JQ, Di	One.	The Cochrane Library	1,308 advanced pancreatic	new option for the treatment of advanced
MY, Zheng	2013;8(3)	and abstracts of recent	cancer patients treated with	pancreatic cancer, with mild but clinically
DY, Chen JZ,	:e57528.	major conferences were	gemcitabine plus erlotinib	meaningful additive efficacy compared
Ding H, Wu	doi:	systematically searched	were included. The reported	with gencitabine alone. Its safety profile

# Table 3: Systematic Reviews and Meta-analyses (Metastatic)

Author/Title	Journal	Patient and Study Characteristics	Results	Conclusion
XY, Huang YF,	10.1371/j	to identify relevant	median progression-free	is generally acceptable, although careful
Mao C, Tang	ournal.po	publications. Studies	survival (or time-to-	management is needed for some specific
JL.	ne.00575	that were conducted in	progression), median overall	adverse events.
JL.	28. Epub	advanced pancreatic	survival, 1-year survival rates,	adverse events.
Gemcitabine	2013 Mar	cancer patients treated	objective response rates and	
plus erlotinib	5.	with gemcitabine plus	disease control rates were 2-	
for advanced	5.	erlotinib (with or	9.6 months, 5-12.5 months,	
pancreatic		without comparison	20%-51%, 0%-28.6% and	
cancer: a		with gemcitabine	25.0%-83.3%, respectively.	
systematic		alone) and reporting	The weighted 1-year survival	
review with		objective response rate,	rate, objective response rate	
		disease control rate,	and disease control rate based	
meta-analysis.		progression-free	on studies reporting robust	
		survival, time-to-	results were 27.9%, 9.1% and	
		progression, overall	57.0%, respectively.	
		1 0		
		survival, 1-year survival rate and/or	According to the studies with	
			relevant data, the incidences of total and severe adverse	
		adverse events were		
		included. Data on	events were 96.3% and	
		objective response rate,	62.9%, respectively. The most	
		disease control rate, 1-	frequently reported adverse	
		year survival rate and	events were leucopenia, rash,	
		adverse events rate,	diarrhea, vomiting,	
		respectively, were	neutropenia,	
		combined mainly by	thrombocytopenia, anaemia,	
		using Meta-Analyst	stomatitis, drug-induced liver	
		software with a	injury, fatigue and fever.	
		random-effects model.	Compared with gemcitabine	
		Data on progression-	alone, the progression-free	
		free survival, time-to-	survival and overall survival	
		progression and overall	with gemcitabine plus	

Author/Title	Journal	Patient and Study Characteristics	Results	Conclusion
Li Y (1), Sun J, Jiang Z, Zhang L, Liu G. Gemcitabine and S-1 combination (GS) chemotherapy versus gemcitabine (GEM) alone for locally advanced and metastatic pancreatic cancer: a meta- analysis of randomized controlled trials in Asia.	J Chemoth er. 2015 Aug;27(4 ):227-34.	•	erlotinib were significantly longer, but there were also more deaths and interstitial lung disease-like syndrome related to this treatment. Meta-analysis of the pooled data demonstrated that the overall response rate (risk ratio, RR = 2.52, 95% confidence interval, CI: 1.85- 3.42, P < 0.00001) and disease control rate (RR = 1.24, 95% CI: 1.12-1.37, P < 0.0001) were significantly different for the GS and GEM alone chemotherapies. Among the group of patients, 43.4% in the GS group and 31.4% in the GEM group survived more than a year. According to this, patients who use the GS regiment may have a better prognosis than the GEM regiment (RR = 1.62, 95% CI: 1.12-2.33, P = 0.04). The combination chemotherapy with GEM and S-1 group had higher	Overall response rate and disease control rate as well as 1-year survival rate in patients who received GS were superior to those treated with GEM alone. Combination chemotherapy with GEM and S-1 may offer greater benefits in the treatment of pancreatic cancer than GEM alone, although the GS group had higher haematological toxicities. Combination chemotherapy with GEM and S-1 might be an option of first-line chemotherapy for pancreatic cancer patients, at least in Asia. Mini Abstract: This systematic review analysing randomized controlled trials (RCTs) comparing S-1 combination chemotherapy versus GEM alone for locally advanced and metastatic pancreatic cancer demonstrated greater efficacy for S-1 combination in term of response, disease control and 1-year survival proportion.
			haematological toxicities including neutropaenia (RR = 1.58, 95% CI: 1.17-	

Author/Title	Journal	Patient and Study Characteristics	Results	Conclusion
		Characteristics	2.14, P = 0.003) and	
			thrombocytopaenia	
			(RR = 1.85, 95% CI: 1.28-	
			2.67, P = 0.001). The	
			incidence of anaemia was	
			much the same in the two	
			groups (RR = 1.22, 95% CI:	
			0.87-1.70, P = 0.24).	
Sultana A(1),	J Clin	There are a large	One hundred thirteen	There was a significant survival benefit
Smith CT,	Oncol.	number of randomized	randomized controlled trials	for chemotherapy over best supportive
Cunningham D,	2007 Jun	controlled trials	were identified, of which 51	care and gemcitabine combinations over
Starling N,	20;25(18)	involving	trials involving 9,970 patients	gemcitabine alone. This supports the use
Neoptolemos	:2607-15.	chemotherapy in the	met the inclusion criteria.	of gemcitabine-based combination
JP, Ghaneh P.		management of	Chemotherapy improved	chemotherapy in the treatment of
		advanced pancreatic	survival compared with best	advanced pancreatic cancer.
Meta-analyses		cancer. Several	supportive care (hazard ratio	
of		chemotherapeutic	[HR] = 0.64; 95% CI, 0.42 to	
chemotherapy		agents, either alone or	0.98). FU-based combination	
for locally advanced and		in combination with	chemotherapy did not result in better overall survival	
		other chemotherapy or		
metastatic		novel agents, have been used. The aim of these	compared with FU alone (HR $= 0.94$ ; 95% CI, 0.82 to 1.08).	
pancreatic cancer.		meta-analyses was to	= 0.94, 95% CI, 0.82 to 1.08). There was insufficient	
cancer.		examine the different	evidence of a survival	
		therapeutic approaches,	difference between	
		and the comparisons	gemcitabine and FU, but the	
		examined were as	wide CI includes clinically	
		follows: chemotherapy	important differences in both	
		versus best supportive	directions, making a clear	
		care; fluorouracil (FU)	conclusion difficult (HR =	
		versus FU combination	0.75; 95% CI, 0.42 to 1.31).	

Author/Title	Journal	Patient and Study Characteristics	Results	Conclusion
		chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy. Relevant trials were identified by searching databases, trial registers, and conference proceedings. The primary end point was overall survival.	Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone (HR = 0.91; 95% CI, 0.85 to 0.97).	
Ying JE(1), Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?	World J Gastroent erol. 2012 Feb 28;18(8): 736-45.	In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States.	Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is only about 6 months. Moreover, phase III trials have shown that adding various cytotoxic and targeted chemotherapeutic agents to gemcitabine has failed to improve overall survival, except in cases in which gemcitabine combined with erlotinib show minimal survival benefit. Several meta-analyses have shown that the combination of	Strikingly, a phase III trial in 2010 showed that, in comparison to gemcitabine alone, the FOLFIRINOX regimen in patients with advanced disease and good performance status, produced better median overall survival, median progression-free survival, and objective response rates. This regimen also resulted in greater, albeit manageable toxicity.

Author/Title	Journal	Patient and Study Characteristics	Results	Conclusion
			gemcitabine with either a	
			platinum analog or	
			capecitabine may lead to	
			clinically relevant survival	
			prolongation, especially for	
			patients with good	
			performance status.	
			Meanwhile, many studies	
			have focused on the	
			pharmacokinetic modulation	
			of gemcitabine by fixed-dose	
			administration, and metabolic	
			or transport enzymes related	
			to the response and toxicity of	
			gemcitabine.	
Banu E(1),	Drugs	We conducted a	Gemcitabine-based doublets	This meta-analysis of data obtained from
Banu A, Fodor	Aging.	systematic review and	were associated with small	randomised controlled phase II-III trials of
A, Landi B,	2007;24(	meta-analysis of	but significant reductions in	patients with advanced pancreatic cancer
Rougier P,	10):865-	published data on the	the risk of death at 6, 12 and	showed a small but significant
Chatellier G,	79.	use of gemcitabine-	18 months of 8% (95% CI 3,	improvement in overall survival for
Andrieu JM,		based doublets	13), 4% (95% CI 2, 7) and 3%	patients receiving gemcitabine-based
Oudard S.		compared with	(95% CI 1, 5), respectively	doublets compared with gemcitabine
		gemcitabine alone in	(p<0.005 for all timepoints).	alone.
Meta-analysis		chemotherapy-naive	No heterogeneity between	
of randomised		patients with advanced	studies was observed.	
trials comparing		and metastatic	Subgroup analyses showed an	
gemcitabine-		pancreatic cancer	overall survival benefit for	
based doublets		treated in randomised	gemcitabine-based doublets in	
versus		controlled phase II-III	clinical trials testing the same	
gemcitabine		trials with overall	planned dose intensity of	
alone in patients		survival as the principal	gemcitabine in comparative	

Author/Title	Journal	Patient and Study	Results	Conclusion
		Characteristics		
with advanced		or secondary endpoint.	arms, using platinum salt-	
and metastatic		To this end, a literature	based protocols and with	
pancreatic		search was performed	survival as the primary	
cancer.		using Cochrane	endpoint.	
		methodology. The		
		relative risks with 95%		
		confidence intervals		
		were estimated based		
		on adjusted number of		
		deaths and patients at		
		risk according to the		
		extent of follow-up and		
		censoring. Twenty-		
		three randomised		
		clinical trials including		
		5886 patients met the		
		inclusion criteria. In		
		these trials, 2932		
		patients were randomly		
		assigned to receive		
		gemcitabine-based		
		doublets and 2954		
		patients to receive		
		gemcitabine alone.		
Zagouri F(1),	Pancreas.	This is the first	The search strategy retrieved	Regarding the evaluation of molecular
Sergentanis TN,	2013	systematic review of	439 articles. Of these articles,	targeted therapies in pancreatic cancer, it
Chrysikos D,	Jul;42(5):	the literature to	237 were irrelevant, 113 were	should be stressed that although multiple
Zografos CG,	760-73.	synthesize all available	reviews, and 21 were case	agents have been tested, only 9 phase 3
Papadimitriou		data coming from trials	reports. After searching the	trials have been conducted and one agent
CÂ,		and evaluate the	references of all reviews and	(erlotinib) has been approved by FDA for
Dimopoulos		efficacy and safety of	remaining articles, 29	use in clinical practice. Nevertheless,

Author/Title	Journal	Patient and Study	Results	Conclusion
		Characteristics		
MA, Filipits M,		molecular targeted	conference abstracts and 15	erlotinib has exhibited modest results, as
Bartsch R.		drugs in unresectable	PubMed articles were also	the gain in survival was only 0.4 months.
		and metastatic	included. Overall, 112 studies	However, molecularly targeted agents
Molecularly		pancreatic cancer.	were eligible for the	seem to mark the beginning of a new era
targeted			systematic review.	in the context of unresectable and
therapies in				metastatic pancreatic cancer. It would be
metastatic				tempting to hypothesize an analogy in
pancreatic				developments after the introduction of
cancer: a				imatinib for the treatment of
systematic				gastrointestinal stromal tumors. In any
review.				event, as molecular profiling surpasses the
				borders of morphological classifications,
				direct consequent molecularly targeted
				therapy may well contribute to the
				individualization of treatment in the
				challenging group of patients with
				metastatic/unresectable pancreatic cancer.
				It is thus anticipated that better selection
				of patients at the individual level will
				contribute to sizably better performance of
				the newly developed and explored
				molecularly targeted agents. Of great
				importance seems to be IGF1R
				monoclonal antibody inhibitors, which
				have entered phase 3 trials.

# Data Supplement 3: Literature Search Strategy for Pancreatic Cancer (Potentially Curable, Locally Advanced, Unresectable and Metastatic) and Health Disparities for Pancreatic Cancer

Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The searches of the English-language literature published from January 2000 to June 2015 combined pancreatic neoplasm terms and follow-up-related terms and MeSH headings. Results of the databases searches were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles, and contributions from Expert Panel members' personal files.

#### **Disease and Treatments**

Search: ("carcinoma, pancreas" [MeSH Terms] OR ((cancer [TIAB] OR neoplasm [TIAB] OR neoplasms[TIAB] OR tumor[TIAB] OR tumors[TIAB] OR tumour[TIAB] OR tumours[TIAB] OR malignant[TIAB] OR malignancy[TIAB] OR malignancies[TIAB] OR carcinoma[TIAB] OR carcinomas[TIAB] OR carcinomatosis[TIAB] OR carcinomatoses[TIAB] OR adenocarcinoma[TIAB] OR adenocarcinomas[TIAB] OR oncology[TIAB] AND ("pancreas"[MeSH Terms] OR "pancreatic"[TIAB])) AND "palliative care"[MeSH Terms] AND ("critical illness" [MeSH Terms] OR "home care services" [MeSH Terms] OR "hospitalization" [MeSH Terms] OR "hospices" [MeSH Terms] OR "terminal care" [MeSH Terms] OR "advance care planning"[MeSH Terms] OR "terminally ill"[MeSH Terms] OR "patient care team" [MeSH Terms] OR "quality of life" [MeSH Terms] OR ("depressive disorder"[MeSH Terms] OR "depression"[MeSH Terms])) AND ((randomized controlled trial[pt] OR controlled clinical trial[pt] OR "randomized controlled trials as topic"[MeSH Terms] OR clinical trial[pt] OR "clinical trial"[tiab] OR "clinical trials"[tiab] OR "clinical trials as topic"[MeSH Terms] OR "controlled clinical trials as topic"[MeSH Terms] OR "randomized controlled trials as topic"[MeSH Terms] OR "clinical trials, phase ii as topic"[MeSH Terms] OR "clinical trials, phase iii as topic"[MeSH Terms] OR "clinical trials, phase iv as topic"[MeSH Terms] OR clinical trial, phase II[pt] OR clinical trial, phase III[pt] OR clinical trial, phase IV[pt] OR "random allocation" [MeSH Terms] OR "random allocation" [tiab] OR "randomly allocated"[tiab] OR "double-blind method"[MeSH Terms] OR "single-blind method"[MeSH Terms]) OR ((random[tiab] OR randomly[tiab] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomisation[tiab]) AND (clinical[tiab] OR control[tiab] OR controlled[tiab] OR "control groups"[MeSH Terms])) OR ((single[tiab] OR single-[tiab] OR double[tiab] OR double-[tiab] OR triple[tiab] OR triple-[tiab] OR multi[tiab] OR multi-[tiab] OR evaluator[tiab] OR assessor[tiab] OR interviewer[tiab]) AND (mask[tiab] OR masked[tiab] OR masking[tiab] OR blind[tiab] OR blinded[tiab] OR blinding[tiab])) OR (("placebos"[MeSH Terms] OR placebo[tiab] OR placebos[tiab] OR random[tiab] OR randomly[tiab] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomization[tiab]) AND ("research design"[MeSH Terms] OR "comparative study"[tiab] OR comparative study[pt] OR "evaluation studies as topic"[MeSH Terms:noexp] OR evaluation studies[pt] OR "evaluation study"[tiab] OR "evaluation studies"[tiab] OR "validation studies as topic"[MeSH Terms] OR "follow-up studies"[MeSH Terms] OR "follow-up study"[tiab] OR "follow up study"[tiab] OR "follow-up studies"[tiab] OR "follow up studies"[tiab] OR "prospective studies"[MeSH Terms] OR prospective[tiab] OR "epidemiologic research design"[MeSH Terms] OR "epidemiologic


methods"[MeSH Terms] OR "epidemiologic study characteristics as topic"[MeSH Terms] OR "epidemiologic studies"[MeSH Terms] OR "intervention studies"[MeSH Terms] OR "cross-over studies"[MeSH Terms]))) NOT (clinical trial, phase I[pt] OR "clinical trials, phase i as topic"[MeSH Terms]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]) NOT review[pt] AND English[la] AND (2002/04/01[PDAT] : 2015/06/01[PDAT])

## **Health Disparities**

(pancreatic cancer treatment) AND (((delivery of health care[MeSH:noexp] OR health behavior[MH] OR health knowledge, attitudes, practice[MH] OR health services accessibility[MH] OR health services, indigenous[MH] OR mass screening[MH] OR mass screening[TIAB] OR mass screenings[TIAB] OR health inequality[TIAB] OR health inequalities[TIAB] OR health inequities[TIAB] OR health inequity[TIAB] OR health services needs and demand[MH] OR patient acceptance of health care[MH] OR patient selection[MH] OR quality of health care[MAJR:noexp] OR quality of life[MH] OR quality of life[TIAB] OR social disparities[TIAB] OR social disparity[TIAB] OR social inequities[TIAB] OR social inequity[TIAB] OR Socioeconomic Factors[MAJR] OR socioeconomic factor[TIAB] OR socioeconomic factors[TIAB]) AND (African American[TIAB] OR African Americans[TIAB] OR African ancestry[TIAB] OR African Continental Ancestry Group[MH] OR AIAN[TIAB] OR American Native Continental Ancestry Group[MH] OR Asian continental ancestry group[MH] OR Asian[TIAB] OR Asians[TIAB] OR black[TIAB] OR blacks[TIAB] OR Caucasian[TIAB] OR Caucasians[TIAB] OR diverse population[TIAB] OR diverse populations[TIAB] OR environmental justice[TIAB] OR ethnic group[TIAB] OR ethnic groups[MH] OR ethnic groups[TIAB] OR ethnic population[TIAB] OR ethnic populations[TIAB] OR ghetto[TIAB] OR ghettos[TIAB] OR Hispanic[TIAB] OR Hispanics[TIAB] OR Indian[TIAB] OR Indians[TIAB] OR Latinos[TIAB] OR Latina[TIAB] OR Latinas[TIAB] OR medically underserved area[MH] OR minority group[TIAB] OR minority groups[MH] OR minority groups[TIAB] OR minority population[TIAB] OR minority populations[TIAB] OR Native American[TIAB] OR Native Americans[TIAB] OR Oceanic Ancestry Group[MH] OR pacific islander[TIAB] OR pacific islanders[TIAB] OR people of color[TIAB] OR poverty area[MH] OR poverty area[TIAB] OR poverty areas[TIAB] OR rural health[MH] OR rural health[TIAB] OR rural health services[MH] OR rural population[MH] OR rural population[TIAB] OR rural populations[TIAB] OR slum[TIAB] OR slums[TIAB] OR urban health[MH] OR urban health services[MH] OR urban population[MH] OR urban population[TIAB] OR urban populations[TIAB] OR vulnerable populations[MH] OR vulnerable population[TIAB] OR vulnerable populations[TIAB] OR white[TIAB] OR whites[TIAB]) OR (ethnic disparities[TIAB] OR ethnic disparity[TIAB] OR health care disparities[TIAB] OR health care disparity[TIAB] OR health disparities[TIAB] OR health disparity[TIAB] OR health status disparities[MH] OR healthcare disparities[MH] OR healthcare disparities[TIAB] OR healthcare disparity[TIAB] OR minority health[MH] OR minority health[TIAB] OR racial disparities[TIAB] OR racial disparity[TIAB] OR racial equality[TIAB] OR racial equity[TIAB] OR racial inequities[TIAB] OR racial inequity[TIAB]))

OR sexual orientation[TIAB] OR sexual identity[TIAB] OR institutional racism[TIAB] OR disability[TIAB] OR special health care needs[TIAB] OR health differences[TIAB] OR social disadvantage[TIAB] OR economic disadvantage[TIAB] OR social obstacles to health[TIAB] OR economic obstacles to health[TIAB] OR social hierarchy[TIAB] OR unequal distribution[TIAB] OR ((ethnic\*[tw] OR race[tw] OR racial[tw] OR disparity[tw] OR disparities[tw] OR blacks[tw] OR blacks[tw] OR black[tw] OR (population groups[mh] OR race relations[mh])))

# Data Supplement 4: Quorum Diagram



## **Data Supplement 5: World Health Organization Definition of Palliative Care<sup>1</sup>**

The World Health Organization has developed this definition of palliative care:

Palliative care is an approach that improves the quality of life of people with localized pancreatic

cancer and their families facing the problems associated with life-threatening illness, through the

prevention and relief of suffering by means of early identification and impeccable assessment

and treatment of pain and other problems, physical, psychosocial and spiritual.

Palliative care:

- provides relief from pain and other distressing symptoms;
- affirms life and regards dying as a normal process;
- intends neither to hasten or postpone death;
- integrates the psychological and spiritual aspects of people with localized pancreatic cancer care;
- offers a support system to help people with localized pancreatic cancer live as actively as possible until death;
- offers a support system to help the family cope during the people with localized pancreatic cancer illness and in their own bereavement;
- uses a team approach to address the needs of people with localized pancreatic cancer and their families, including bereavement counseling, if indicated;
- will enhance quality of life, and may also positively influence the course of illness;
- is applicable early in the course of illness, in conjunction with other therapies that are intended to prolong life, such as surgery and chemotherapy, and includes those investigations needed to better understand and manage distressing clinical complications.

# Data Supplement 6: Pancreatic Protocol Computerized Tomography (CT)<sup>2,3</sup>

To assess resectability and staging, a pancreatic protocol CT or CT angiography is performed. To perform the CT angiography:

- Bolus administration of iodinated nonionic contrast
- Imaging in arterial and venous phases
- First 30 seconds (arterial phase), maximizes attenuation of celiac axis, superior mesenteric artery, and peripancreatic arteries
- 60 to 70 seconds after start of the contrast injection (portal venous phase) provides enhancement for imaging of superior mesenteric vein, splenic and portal veins
- Portal venous phase also provides enhancement for imaging of pancreas and liver metastases
- 70 to 80 seconds after contrast injection (hepatic phase) provides enhancement for imaging of additional liver metastases

# References

1. World Health Organization Definition of Palliative Care: Definition of Palliative Care, <u>http://www.who.int/cancer/palliative/definition/en/</u>, 2015

2. Tummala P, Junaidi O, Agarwal B: Imaging of pancreatic cancer: An overview. J Gastrointest Oncol 2:168-174, 2011

3. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 6:1301-1308, 2008